Difference between revisions of "Paclitaxel (Taxol)"
m |
Warner-admin (talk | contribs) m (Text replacement - "[http://www.thomsonhc.com/home/dispatch Micromedex]" to "Micromedex") |
||
(43 intermediate revisions by 3 users not shown) | |||
Line 1: | Line 1: | ||
==General information== | ==General information== | ||
− | Class/mechanism: Taxane, promotes assembly of microtubules, stablizes microtubules, preventing depolymerization. Paclitaxel interferes with the normal dynamic reorganization of microtubules that is necessary for regular interphase/mitosis processes. It also leads to creation of abnormal bundles of microtubules. Paclitaxel is highly lipophilic/insoluble in water and needs to be dissolved in Cremophor EL (polyoxyethylated castor oil), which may cause hypersensitivity infusion reactions.<ref name="insert">[http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020262s049lbl.pdf Paclitaxel (Taxol) package insert]</ref><ref>[[ | + | Class/mechanism: Taxane, promotes assembly of microtubules, stablizes microtubules, preventing depolymerization. Paclitaxel interferes with the normal dynamic reorganization of microtubules that is necessary for regular interphase/mitosis processes. It also leads to creation of abnormal bundles of microtubules. Paclitaxel is highly lipophilic/insoluble in water and needs to be dissolved in Cremophor EL (polyoxyethylated castor oil), which may cause hypersensitivity infusion reactions.<ref name="insert">[http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020262s049lbl.pdf Paclitaxel (Taxol) package insert]</ref><ref>[[:File:Paclitaxel.pdf | Paclitaxel (Taxol) package insert (locally hosted backup)]]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: [[irritant]] (usually), [[vesicant]] (rare) | <br>Extravasation: [[irritant]] (usually), [[vesicant]] (rare) | ||
− | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> |
+ | |||
+ | ==Diseases for which it is established ''(work in progress)''== | ||
+ | *[[Breast cancer]] | ||
+ | *[[Kaposi sarcoma]] | ||
+ | *[[Non-small cell lung cancer]] | ||
+ | **[[Non-small cell lung cancer, nonsquamous]] | ||
+ | **[[Non-small cell lung cancer, squamous]] | ||
+ | *[[Ovarian cancer]] | ||
+ | **[[Low-grade serous ovarian cancer]] | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
<div style="column-count:3;-moz-column-count:3;-webkit-column-count:3"> | <div style="column-count:3;-moz-column-count:3;-webkit-column-count:3"> | ||
− | *[[ | + | *[[Anal cancer]] |
+ | *[[Angiosarcoma]] | ||
+ | *[[Carcinoma of unknown primary]] | ||
+ | *[[Cervical cancer]] | ||
*[[Cutaneous basal cell carcinoma]] | *[[Cutaneous basal cell carcinoma]] | ||
− | |||
− | |||
− | |||
*[[Diffuse large B-cell lymphoma]] | *[[Diffuse large B-cell lymphoma]] | ||
+ | *[[Endometrial cancer]] | ||
*[[Esophageal cancer]] | *[[Esophageal cancer]] | ||
+ | **[[Esophageal adenocarcinoma]] | ||
+ | **[[Esophageal squamous cell carcinoma]] | ||
*[[Gastric cancer]] | *[[Gastric cancer]] | ||
*[[Head and neck cancer]] | *[[Head and neck cancer]] | ||
− | *[[Melanoma]] | + | *[[Melanoma]] |
− | *[[ | + | *[[Nasopharyngeal carcinoma]] |
− | |||
*[[Penile cancer]] | *[[Penile cancer]] | ||
*[[Prostate cancer]] | *[[Prostate cancer]] | ||
− | |||
*[[Small cell lung cancer]] | *[[Small cell lung cancer]] | ||
*[[Testicular cancer]] | *[[Testicular cancer]] | ||
*[[Thymoma]] | *[[Thymoma]] | ||
− | *[[ | + | *[[Urothelial carcinoma]] |
− | *[[ | + | **[[Bladder cancer]] |
*[[Vulvar cancer]] | *[[Vulvar cancer]] | ||
</div> | </div> | ||
==Patient drug information== | ==Patient drug information== | ||
*[http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020262s049lbl.pdf Paclitaxel (Taxol) package insert]<ref name="insert"></ref> | *[http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020262s049lbl.pdf Paclitaxel (Taxol) package insert]<ref name="insert"></ref> | ||
− | *[ | + | *[https://chemocare.com/druginfo/Paclitaxel.aspx Paclitaxel (Taxol) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/Paclitaxel.aspx Paclitaxel (Taxol) patient drug information (Chemocare)]</ref> |
*[http://www.uptodate.com/contents/paclitaxel-patient-drug-information Paclitaxel (Taxol) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/paclitaxel-patient-drug-information Paclitaxel (Taxol) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/paclitaxel-patient-drug-information Paclitaxel (Taxol) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/paclitaxel-patient-drug-information Paclitaxel (Taxol) patient drug information (UpToDate)]</ref> | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
− | * | + | ===[[Breast cancer]]=== |
− | * | + | * 1998-04-09 (oldest label available at Drugs @ FDA): Indicated for the treatment of [[Breast cancer | breast cancer]] after failure of combination therapy for metastatic disease. Prior therapy should have included an [[:Category:Anthracyclines|anthracycline]] unless clinically contraindicated. ''(Based on Nabholtz et al. 1996)'' |
− | + | * 1998-04-09 (oldest label available at Drugs @ FDA): Indicated for the treatment of [[Breast cancer | breast cancer]] relapsed within 6 months of adjuvant chemotherapy. Prior therapy should have included an [[:Category:Anthracyclines|anthracycline]] unless clinically contraindicated. ''(Based on Nabholtz et al. 1996)'' | |
− | + | * 1999-10-25: New indication for the adjuvant treatment of node-positive [[Breast cancer | breast cancer]] administered sequentially to standard [[Doxorubicin (Adriamycin) | doxorubicin]]-containing combination chemotherapy. ''(Based on INT 0148/CALGB 9344)'' | |
− | + | ===[[Ovarian cancer]]=== | |
− | * | + | * 1992-12-29: Initial FDA approval for treatment of patients with metastatic [[Ovarian cancer|carcinoma of the ovary]] after failure of first-line or subsequent chemotherapy. ''(Based on Eisenhauer et al. 1994)'' |
− | * | + | * 1998-04-09 (oldest label available at Drugs @ FDA): Indicated for first-line therapy in combination with [[Cisplatin (Platinol) | cisplatin]] for the treatment of advanced [[Ovarian cancer | carcinoma of the ovary]]. ''(Based on GOG 111 & OV10)'' |
+ | * 1998-04-09 (oldest label available at Drugs @ FDA): Indicated for subsequent therapy for the treatment of advanced [[Ovarian cancer | carcinoma of the ovary]]. ''(Based on GOG 111 & OV10)'' | ||
+ | ===[[Kaposi sarcoma]]=== | ||
+ | * 1998-04-09 (oldest label available at Drugs @ FDA): Indicated for the second-line treatment of [[Kaposi sarcoma | AIDS-related Kaposi's sarcoma]]. ''(Based on CA139-174 & CA139-281)'' | ||
+ | ===[[Non-small cell lung cancer]]=== | ||
+ | * 1998-06-30: New indication added: in combination with [[Cisplatin (Platinol) | cisplatin]], is indicated for the first-line treatment of [[non-small cell lung cancer]] in patients who are not candidates for potentially curative surgery and/or radiation therapy. ''(Based on ECOG E5592)'' | ||
+ | ==History of changes in EMA indication== | ||
+ | *1992-12-29: EURD | ||
+ | ==History of changes in PMDA indication== | ||
+ | *2005-05-31: New indication for the treatment of [[endometrial cancer|cancer of the uterus body]]. | ||
+ | *2012-03-21: New additional indications and new dosages for the treatment of relapsed or metastatic [[head and neck cancer]]. | ||
+ | *2012-03-21: New additional indications and new dosages for the treatment of relapsed or metastatic [[Esophageal cancer|esophagus cancer]]. | ||
+ | *2012-03-21: New additional indications and new dosages for the treatment of [[angiosarcoma]]. | ||
+ | *2012-03-21: New additional indications and new dosages for the treatment of advanced or relapsed [[cervical cancer]]. | ||
+ | *2013-02-21: New additional indications and a new dosage for the treatment of relapsed or refractory germ cell tumors (testicular tumors, ovarian tumors, extragonadal tumors). | ||
==Also known as== | ==Also known as== | ||
Line 53: | Line 77: | ||
|Anzatax | |Anzatax | ||
|Anzatec | |Anzatec | ||
+ | |Apealea | ||
|Asotax | |Asotax | ||
|Betaxel | |Betaxel | ||
|Bristaxol | |Bristaxol | ||
+ | |- | ||
|Britaxol | |Britaxol | ||
− | |||
|Clitaxel | |Clitaxel | ||
|Cytax | |Cytax | ||
Line 65: | Line 90: | ||
|Ebetaxel | |Ebetaxel | ||
|Formoxol | |Formoxol | ||
− | |||
|- | |- | ||
+ | |Genexol | ||
|Genetaxyl | |Genetaxyl | ||
|Gros | |Gros | ||
Line 74: | Line 99: | ||
|Medixel | |Medixel | ||
|Mitotax | |Mitotax | ||
+ | |- | ||
|Neotacs | |Neotacs | ||
− | |||
|Neotaxan | |Neotaxan | ||
|Neotaxl | |Neotaxl | ||
Line 82: | Line 107: | ||
|Onxol | |Onxol | ||
|Paclitax | |Paclitax | ||
− | |||
|Paclitaxin | |Paclitaxin | ||
|- | |- | ||
Line 95: | Line 119: | ||
|- | |- | ||
|Paxus | |Paxus | ||
+ | |Pazenir | ||
|Petaxel | |Petaxel | ||
|Phyxol | |Phyxol | ||
Line 101: | Line 126: | ||
|Ribotax | |Ribotax | ||
|Sindaxel | |Sindaxel | ||
+ | |- | ||
|Taclipaxol | |Taclipaxol | ||
− | |||
|Tarvexol | |Tarvexol | ||
|Taxocris | |Taxocris | ||
Line 110: | Line 135: | ||
|Taycovit | |Taycovit | ||
|Unitaxel | |Unitaxel | ||
+ | |- | ||
|Yewtaxan | |Yewtaxan | ||
+ | |Naveruclif | ||
|- | |- | ||
|} | |} | ||
+ | |||
==References== | ==References== | ||
<references/> | <references/> | ||
Line 119: | Line 147: | ||
[[Category:Intracavitary medications]] | [[Category:Intracavitary medications]] | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
− | [[Category:Irritant | + | [[Category:Irritant]] |
− | [[Category:Vesicant | + | [[Category:Vesicant]] |
[[Category:Taxanes]] | [[Category:Taxanes]] | ||
[[Category:Microtubule inhibitors]] | [[Category:Microtubule inhibitors]] | ||
− | [[Category: | + | [[Category:Anal cancer medications]] |
− | [[Category: | + | [[Category:Angiosarcoma medications]] |
[[Category:Bladder cancer medications]] | [[Category:Bladder cancer medications]] | ||
[[Category:Breast cancer medications]] | [[Category:Breast cancer medications]] | ||
+ | [[Category:Carcinoma of unknown primary medications]] | ||
[[Category:Cervical cancer medications]] | [[Category:Cervical cancer medications]] | ||
+ | [[Category:Cutaneous basal cell carcinoma medications]] | ||
[[Category:Diffuse large B-cell lymphoma medications]] | [[Category:Diffuse large B-cell lymphoma medications]] | ||
[[Category:Endometrial cancer medications]] | [[Category:Endometrial cancer medications]] | ||
+ | [[Category:Esophageal adenocarcinoma medications]] | ||
[[Category:Esophageal cancer medications]] | [[Category:Esophageal cancer medications]] | ||
+ | [[Category:Esophageal squamous cell carcinoma medications]] | ||
[[Category:Gastric cancer medications]] | [[Category:Gastric cancer medications]] | ||
[[Category:Head and neck cancer medications]] | [[Category:Head and neck cancer medications]] | ||
+ | [[Category:Kaposi sarcoma medications]] | ||
+ | [[Category:Low-grade serous ovarian cancer medications]] | ||
[[Category:Melanoma medications]] | [[Category:Melanoma medications]] | ||
+ | [[Category:Nasopharyngeal carcinoma medications]] | ||
[[Category:Non-small cell lung cancer medications]] | [[Category:Non-small cell lung cancer medications]] | ||
+ | [[Category:Non-small cell lung cancer, nonsquamous medications]] | ||
+ | [[Category:Non-small cell lung cancer, squamous medications]] | ||
[[Category:Ovarian cancer medications]] | [[Category:Ovarian cancer medications]] | ||
[[Category:Penile cancer medications]] | [[Category:Penile cancer medications]] | ||
[[Category:Prostate cancer medications]] | [[Category:Prostate cancer medications]] | ||
− | |||
[[Category:Small cell lung cancer medications]] | [[Category:Small cell lung cancer medications]] | ||
[[Category:Testicular cancer medications]] | [[Category:Testicular cancer medications]] | ||
[[Category:Thymoma medications]] | [[Category:Thymoma medications]] | ||
− | [[Category: | + | [[Category:Urothelial carcinoma medications]] |
[[Category:Vulvar cancer medications]] | [[Category:Vulvar cancer medications]] | ||
[[Category:FDA approved in 1992]] | [[Category:FDA approved in 1992]] | ||
+ | [[Category:EMA approved in 1992]] | ||
[[Category:PMDA approved drugs]] | [[Category:PMDA approved drugs]] | ||
[[Category:WHO Essential Cancer Medicine]] | [[Category:WHO Essential Cancer Medicine]] |
Latest revision as of 01:48, 29 June 2024
General information
Class/mechanism: Taxane, promotes assembly of microtubules, stablizes microtubules, preventing depolymerization. Paclitaxel interferes with the normal dynamic reorganization of microtubules that is necessary for regular interphase/mitosis processes. It also leads to creation of abnormal bundles of microtubules. Paclitaxel is highly lipophilic/insoluble in water and needs to be dissolved in Cremophor EL (polyoxyethylated castor oil), which may cause hypersensitivity infusion reactions.[1][2]
Route: IV
Extravasation: irritant (usually), vesicant (rare)
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is established (work in progress)
Diseases for which it is used
- Anal cancer
- Angiosarcoma
- Carcinoma of unknown primary
- Cervical cancer
- Cutaneous basal cell carcinoma
- Diffuse large B-cell lymphoma
- Endometrial cancer
- Esophageal cancer
- Gastric cancer
- Head and neck cancer
- Melanoma
- Nasopharyngeal carcinoma
- Penile cancer
- Prostate cancer
- Small cell lung cancer
- Testicular cancer
- Thymoma
- Urothelial carcinoma
- Vulvar cancer
Patient drug information
- Paclitaxel (Taxol) package insert[1]
- Paclitaxel (Taxol) patient drug information (Chemocare)[3]
- Paclitaxel (Taxol) patient drug information (UpToDate)[4]
History of changes in FDA indication
Breast cancer
- 1998-04-09 (oldest label available at Drugs @ FDA): Indicated for the treatment of breast cancer after failure of combination therapy for metastatic disease. Prior therapy should have included an anthracycline unless clinically contraindicated. (Based on Nabholtz et al. 1996)
- 1998-04-09 (oldest label available at Drugs @ FDA): Indicated for the treatment of breast cancer relapsed within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. (Based on Nabholtz et al. 1996)
- 1999-10-25: New indication for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. (Based on INT 0148/CALGB 9344)
Ovarian cancer
- 1992-12-29: Initial FDA approval for treatment of patients with metastatic carcinoma of the ovary after failure of first-line or subsequent chemotherapy. (Based on Eisenhauer et al. 1994)
- 1998-04-09 (oldest label available at Drugs @ FDA): Indicated for first-line therapy in combination with cisplatin for the treatment of advanced carcinoma of the ovary. (Based on GOG 111 & OV10)
- 1998-04-09 (oldest label available at Drugs @ FDA): Indicated for subsequent therapy for the treatment of advanced carcinoma of the ovary. (Based on GOG 111 & OV10)
Kaposi sarcoma
- 1998-04-09 (oldest label available at Drugs @ FDA): Indicated for the second-line treatment of AIDS-related Kaposi's sarcoma. (Based on CA139-174 & CA139-281)
Non-small cell lung cancer
- 1998-06-30: New indication added: in combination with cisplatin, is indicated for the first-line treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy. (Based on ECOG E5592)
History of changes in EMA indication
- 1992-12-29: EURD
History of changes in PMDA indication
- 2005-05-31: New indication for the treatment of cancer of the uterus body.
- 2012-03-21: New additional indications and new dosages for the treatment of relapsed or metastatic head and neck cancer.
- 2012-03-21: New additional indications and new dosages for the treatment of relapsed or metastatic esophagus cancer.
- 2012-03-21: New additional indications and new dosages for the treatment of angiosarcoma.
- 2012-03-21: New additional indications and new dosages for the treatment of advanced or relapsed cervical cancer.
- 2013-02-21: New additional indications and a new dosage for the treatment of relapsed or refractory germ cell tumors (testicular tumors, ovarian tumors, extragonadal tumors).
Also known as
- Brand names:
Synonyms | |||||||
---|---|---|---|---|---|---|---|
Abitaxel | Altaxel | Anzatax | Anzatec | Apealea | Asotax | Betaxel | Bristaxol |
Britaxol | Clitaxel | Cytax | Daburex | Dalys | Drifen | Ebetaxel | Formoxol |
Genexol | Genetaxyl | Gros | Ifaxol | Intaxel | Magytax | Medixel | Mitotax |
Neotacs | Neotaxan | Neotaxl | Ofoxel | Oncotaxel | Onxol | Paclitax | Paclitaxin |
Pacliteva | Pacxel | Padexol | Paklitaxfil | Panataxel | Parexel | Paxene | Paxenor |
Paxus | Pazenir | Petaxel | Phyxol | Poltaxel | Praxel | Ribotax | Sindaxel |
Taclipaxol | Tarvexol | Taxocris | Taxodiol | Taxol | Taxomedac | Taycovit | Unitaxel |
Yewtaxan | Naveruclif |
References
- Drugs
- Intracavitary medications
- Intravenous medications
- Irritant
- Vesicant
- Taxanes
- Microtubule inhibitors
- Anal cancer medications
- Angiosarcoma medications
- Bladder cancer medications
- Breast cancer medications
- Carcinoma of unknown primary medications
- Cervical cancer medications
- Cutaneous basal cell carcinoma medications
- Diffuse large B-cell lymphoma medications
- Endometrial cancer medications
- Esophageal adenocarcinoma medications
- Esophageal cancer medications
- Esophageal squamous cell carcinoma medications
- Gastric cancer medications
- Head and neck cancer medications
- Kaposi sarcoma medications
- Low-grade serous ovarian cancer medications
- Melanoma medications
- Nasopharyngeal carcinoma medications
- Non-small cell lung cancer medications
- Non-small cell lung cancer, nonsquamous medications
- Non-small cell lung cancer, squamous medications
- Ovarian cancer medications
- Penile cancer medications
- Prostate cancer medications
- Small cell lung cancer medications
- Testicular cancer medications
- Thymoma medications
- Urothelial carcinoma medications
- Vulvar cancer medications
- FDA approved in 1992
- EMA approved in 1992
- PMDA approved drugs
- WHO Essential Cancer Medicine